Teva Pharmaceutical Industries (TEVA) News Today $16.43 -0.32 (-1.91%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down - Should You Sell?Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down - Should You Sell?November 15 at 12:50 PM | marketbeat.comKing Wealth Management Group Acquires New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)King Wealth Management Group bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 98,102 shares of the companNovember 15 at 8:28 AM | marketbeat.comPlato Investment Management Ltd Makes New $1.14 Million Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Plato Investment Management Ltd bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 63,530 shares of the company's stock, valuedNovember 15 at 6:13 AM | marketbeat.comSivik Global Healthcare LLC Sells 30,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Sivik Global Healthcare LLC trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 15.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,000 shares of the companyNovember 14 at 10:01 AM | marketbeat.comTeva Pharmaceutical Industries Limited Announces Financial Results for the Period Ended September 30, 2024November 14 at 4:11 AM | americanbankingnews.comWCM Investment Management LLC Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)WCM Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 60,170 shares of the company's stock, valued at approximately $1,0November 13, 2024 | marketbeat.comFMR LLC Bolsters Stake in Teva Pharmaceutical Industries LtdNovember 12, 2024 | gurufocus.comMivtachim The Workers Social Insurance Fund Ltd. Under Special Management Has $24.97 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,385,731 shares of the company's stNovember 10, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Migdal Insurance & Financial Holdings Ltd.Migdal Insurance & Financial Holdings Ltd. decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owNovember 10, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by ARK Investment Management LLCARK Investment Management LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 26.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 123,865 shares of the company's stock afteNovember 9, 2024 | marketbeat.comEquities Analysts Offer Predictions for TEVA FY2024 EarningsNovember 9, 2024 | americanbankingnews.comTeva to Present at the Jefferies London Healthcare ConferenceNovember 8, 2024 | globenewswire.comTeva selloff brings good entry point, says UBSNovember 8, 2024 | markets.businessinsider.comRobeco Institutional Asset Management B.V. Boosts Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Robeco Institutional Asset Management B.V. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 73.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 465,032 shares of the company's stock after acquiriNovember 8, 2024 | marketbeat.comMarket Whales and Their Recent Bets on TEVA OptionsNovember 7, 2024 | benzinga.comStrong Performance and Strategic Initiatives Bolster Buy Rating for Teva PharmaceuticalsNovember 7, 2024 | markets.businessinsider.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comTeva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...November 7, 2024 | finance.yahoo.comZacks Research Issues Optimistic Estimate for TEVA EarningsTeva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research upped their FY2024 earnings per share estimates for shares of Teva Pharmaceutical Industries in a report released on Monday, November 4th. Zacks Research analyst R. Department now forecasts thNovember 7, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comTeva Pharm CEO says will work productively with Trump administrationNovember 6, 2024 | reuters.comTeva Pharmaceutical Industries (NYSE:TEVA) Releases FY24 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) updated its FY24 earnings guidance. The company provided EPS guidance of $2.40-2.50 for the period, compared to the consensus estimate of $2.45. The company also issued revenue guidance of $16.10-16.50 billionillion, compared to the consensus estimate of $16.27 billionillion.November 6, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comTeva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2024 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2024 earnings guidance. The company provided EPS guidance of 2.400-2.500 for the period, compared to the consensus estimate of 2.450. The company also issued revenue guidance of $16.1 billionillion-$16.5 billionillion, compared to the consensus estimate of $16.3 billionillion.November 6, 2024 | marketbeat.comTeva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock UpNovember 6, 2024 | markets.businessinsider.comZacks Research Has Optimistic Outlook of TEVA Q3 EarningsTeva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research note issued on Monday, November 4th. Zacks Research analyst R. Department now anticipates thNovember 6, 2024 | marketbeat.comTeva Pharmaceutical third-quarter profit, revenue top estimatesNovember 6, 2024 | reuters.comTeva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPSNovember 6, 2024 | globenewswire.comNational Pension Service Has $57.14 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)National Pension Service lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 107.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,170,640 shares of the company's stock after purchasing an additional 1,640,940 sharesNovember 6, 2024 | marketbeat.com236,765 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Greenwood Capital Associates LLCGreenwood Capital Associates LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchasedNovember 5, 2024 | marketbeat.comPrivate Management Group Inc. Reduces Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Private Management Group Inc. lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,273,997 shares of the company's stock after selNovember 2, 2024 | marketbeat.comTeva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749November 2, 2024 | markets.businessinsider.comTeva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing Patient Experience VariationsNovember 2, 2024 | markets.businessinsider.comTeva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric ConditionNovember 1, 2024 | globenewswire.comTeva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)November 1, 2024 | globenewswire.com34,790 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Diversify Wealth Management LLCDiversify Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,790 shares of the comNovember 1, 2024 | marketbeat.comDrugmaker Teva Pharmaceuticals fined $500M by European regulatorsOctober 31, 2024 | msn.comTeva issues a statement on the European Commission’s decision on COPAXONEOctober 31, 2024 | markets.businessinsider.comAustralianSuper Pty Ltd Sells 611,726 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)AustralianSuper Pty Ltd trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,893,376 shares of the company's stock after sellingOctober 31, 2024 | marketbeat.comTeva fined $500M by European Commission for disparaging rival MS drugOctober 31, 2024 | msn.comTeva Statement on European Commission Decision; Company to AppealOctober 31, 2024 | globenewswire.comTeva fined $503 mln by EU for disparaging rival productOctober 31, 2024 | reuters.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsTeva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and sevenOctober 30, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by GHP Investment Advisors Inc.GHP Investment Advisors Inc. boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1,681.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,065 sharesOctober 28, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Significant Drop in Short InterestTeva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 19,910,000 shares, a drop of 18.7% from the September 30th total of 24,490,000 shares. Based on an average daily trading volume, of 7,430,000 shares, the days-to-cover ratio is presently 2.7 days.October 28, 2024 | marketbeat.comInvestors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past yearOctober 26, 2024 | finance.yahoo.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 244.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,389,84October 26, 2024 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Price Target Increased to $25.00 by Analysts at BarclaysBarclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday.October 23, 2024 | marketbeat.comTeva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower DebtOctober 23, 2024 | seekingalpha.comAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)October 22, 2024 | globenewswire.com Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov TEVA Media Mentions By Week TEVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEVA News Sentiment▼1.080.55▲Average Medical News Sentiment TEVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TEVA Articles This Week▼98▲TEVA Articles Average Week Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News TAK News BNTX News MRNA News BGNE News GMAB News SMMT News VTRS News PCVX News SRPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TEVA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
